MHRA approves Ogsiveo for adult desmoid tumours in UK

Today, 7 January 2026, the UK’s medicines regulator, the MHRA, approved Ogsiveo (nirogacestat hydrobromide) for adults with progressing desmoid tumours. If you or your students are hearing this name for the first time, here’s the clear version to start with.

Desmoid tumours are growths that form in connective tissue, often in the arms, legs or abdomen. They are not cancer, but as they grow they can damage nearby tissue and be difficult to remove. That’s why slowing or stopping growth matters, as the MHRA explains.

Ogsiveo works by blocking proteins involved in tumour growth. In studies referenced by the MHRA, adults taking nirogacestat hydrobromide lived longer without their condition getting worse, and some avoided the need for potential surgery. That benefit underpins today’s approval.

What this means: for some adults, a medicine-first option may help manage symptoms, delay invasive procedures and protect quality of life. Decisions are personal and should be made with a specialist team that understands your tumour’s location and behaviour.

As with any medicine, there are side effects. Common ones include diarrhoea, rash, nausea, tiredness, hypophosphataemia (low levels of phosphate in the blood), headache, and stomatitis (inflammation of the mouth lining). Tell your care team promptly if these occur or change.

There is a serious risk to discuss at the outset: premature menopause, which may affect more than 1 in 10 people. The MHRA also warns that Ogsiveo may harm an unborn baby and that effects on ovaries, testicles and fertility are not fully known. The medicine must not be taken during pregnancy, and highly effective contraception is required.

To support pregnancy prevention, patients will receive a card with clear instructions. The MHRA says this applies to female patients taking Ogsiveo and to female partners of male patients on the medicine. Keep the card with you and show it to pharmacists, nurses and doctors.

For the full picture, check the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SmPC), which the MHRA will publish within seven days of approval. If you suspect a side effect, speak to a healthcare professional and report it to the Yellow Card scheme at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app on Google Play or the Apple App Store.

How approval happened: the decision was granted on 7 January 2026 under the International Recognition Procedure, using the European Medicines Agency as the reference regulator. The EMA file number is EMEA/H/C/006071/0000. As with all licensed medicines, the MHRA will keep monitoring safety and effectiveness.

Quick glossary to teach with: desmoid tumour-non-cancerous growth in connective tissue; MHRA-the UK regulator for medicines and medical devices; Ogsiveo/nirogacestat hydrobromide-the medicine approved today; PIL-leaflet for patients; SmPC-detailed information for clinicians; Yellow Card-the UK system for reporting suspected side effects; IRP-a route that lets the MHRA recognise trusted regulators’ assessments.

For classrooms and families: use this as a case study in reading health announcements. Note the date (7 January 2026), the condition, the benefits claimed and the risks-especially premature menopause. Then list the questions you would ask a clinician before starting treatment, including how contraception and monitoring will work for you.